Listen
ONCASPAR (E. coli asparaginase), antineoplastic agent
HAEMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Oct 13 2016
Reason for request
Inclusion
No clinical benefit demonstrated by comparison with KIDROLASE in the management of newly diagnosed or relapsed acute lymphoblastic leukaemia in patients without hypersensitivity to native E. coli asparaginase.
- ONCASPAR has Marketing Authorisation in combination with other antineoplastic agents for the treatment of acute lymphoblastic leukaemia in children and adults.
- It is a first-line treatment of newly diagnosed or relapsed acute lymphoblastic leukaemia in patients without hypersensitivity (clinical allergy or silent inactivation) to native E. coli asparaginase (KIDROLASE).
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
